We consider that a relatively lower IL-6 level (median, 4.0 pg/mL; range, 2.4–9.5 pg/mL) in our cohort, compared with patients with lung cancer (15) and inflammatory-bowel disease (53), represents a stable clinical state, which may mask a potential relationship between IL-6 and REE. Here, IL6 is linked to lung cancer.